Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies
A Digital Publication for the Practicing Medical Specialist, Industry Executive, & Investor
Advancing next-generation RNA therapeutics beyond the liver through breakthrough delivery technologies